Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$18.47
+0.7%
$19.78
$10.21
$25.67
$4.38B0.433.67 million shs2.10 million shs
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
$2.72
+7.1%
$2.48
$1.78
$10.14
$53.06M0.7263,894 shs202,480 shs
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
$4.41
$1.35
$50.10
$3.66M1.04227,964 shs650,294 shs
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
$0.38
-0.9%
$0.35
$0.22
$3.28
$22.63M1.481.49 million shs277,318 shs
Miromatrix Medical Inc. stock logo
MIRO
Miromatrix Medical
$3.39
$3.38
$0.91
$4.35
$92.95M0.0180,095 shsN/A
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
+0.71%+0.96%-11.46%-4.79%+53.92%
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
+7.09%+14.05%-2.51%-20.70%-65.04%
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
0.00%0.00%0.00%0.00%-92.21%
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
-0.92%-1.66%-1.07%+35.21%-85.66%
Miromatrix Medical Inc. stock logo
MIRO
Miromatrix Medical
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
4.1804 of 5 stars
3.72.00.00.03.02.53.1
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
4.0962 of 5 stars
3.43.00.04.80.02.50.6
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
1.2629 of 5 stars
3.80.00.00.00.60.00.0
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
1.7415 of 5 stars
3.02.00.00.01.21.70.6
Miromatrix Medical Inc. stock logo
MIRO
Miromatrix Medical
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
3.33
Buy$27.6749.79% Upside
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
2.80
Moderate Buy$23.80775.00% Upside
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
3.50
Strong Buy$6.00∞ Upside
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
2.00
Hold$3.39794.27% Upside
Miromatrix Medical Inc. stock logo
MIRO
Miromatrix Medical
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ELEV, MIRO, ADVM, APTO, and ADMA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$16.00 ➝ $12.00
6/10/2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
6/10/2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Neutral
6/9/2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/9/2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/15/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$5.00 ➝ $4.00
5/15/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
5/15/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
5/8/2025
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $32.00
4/17/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$40.00 ➝ $33.00
4/16/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$10.00 ➝ $5.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$426.45M10.34$0.55 per share33.88$1.48 per share12.48
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
$1M56.82N/AN/A$3.40 per share0.80
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
N/AN/AN/AN/A($0.19) per shareN/A
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
N/AN/AN/AN/A$1.02 per shareN/A
Miromatrix Medical Inc. stock logo
MIRO
Miromatrix Medical
$958.03K97.02N/AN/A$1.25 per share2.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$197.67M$0.8521.7326.77N/A45.01%47.16%30.51%8/6/2025 (Estimated)
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
-$130.93M-$6.40N/AN/AN/AN/A-130.53%-66.31%8/11/2025 (Estimated)
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
-$51.21M-$89.19N/AN/AN/AN/A-5,683.22%-300.44%N/A
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
-$44.49M-$0.82N/AN/AN/AN/A-74.68%-48.14%8/5/2025 (Estimated)
Miromatrix Medical Inc. stock logo
MIRO
Miromatrix Medical
-$29.96M-$1.14N/AN/A-2,861.17%-120.49%-90.70%N/A

Latest ELEV, MIRO, ADVM, APTO, and ADMA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
-$0.26N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
-$0.20-$0.24-$0.04-$0.24N/AN/A
5/7/2025Q1 2025
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$0.16$0.14-$0.02$0.11$116.40 million$114.80 million
4/15/2025Q4 2024
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
-$1.34-$1.96-$0.62-$1.96N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
N/AN/AN/AN/AN/A
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
N/AN/AN/AN/AN/A
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
N/AN/AN/AN/AN/A
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
N/AN/AN/AN/AN/A
Miromatrix Medical Inc. stock logo
MIRO
Miromatrix Medical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
0.22
6.58
3.36
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
N/A
3.57
3.57
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
N/A
1.05
1.05
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
0.67
19.40
19.40
Miromatrix Medical Inc. stock logo
MIRO
Miromatrix Medical
0.02
3.46
3.46

Institutional Ownership

CompanyInstitutional Ownership
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
75.68%
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
48.17%
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
26.62%
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
83.70%
Miromatrix Medical Inc. stock logo
MIRO
Miromatrix Medical
29.38%
CompanyEmployeesShares OutstandingFree FloatOptionable
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
530238.73 million230.38 millionOptionable
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
19020.89 million19.64 millionOptionable
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
312.14 million63.45 millionNo Data
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
4059.22 million54.43 millionOptionable
Miromatrix Medical Inc. stock logo
MIRO
Miromatrix Medical
7627.42 million25.99 millionOptionable

Recent News About These Companies

Turning pig organs to human organs
Walter Reed Army Medical Center
Q4 2023 United Therapeutics Corp Earnings Call
Best Stocks to Buy Right Now
Miromatrix Holder Says It Omitted United Therapeutics Deal Info
Miromatrix Reports Third Quarter 2023 Results
United Therapeutics buying Miromatrix for up to $140M

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
ADMA Biologics stock logo

ADMA Biologics NASDAQ:ADMA

$18.47 +0.13 (+0.71%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$18.75 +0.28 (+1.51%)
As of 04:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Adverum Biotechnologies stock logo

Adverum Biotechnologies NASDAQ:ADVM

$2.72 +0.18 (+7.09%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$2.68 -0.04 (-1.47%)
As of 04:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Aptose Biosciences stock logo

Aptose Biosciences NASDAQ:APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Elevation Oncology stock logo

Elevation Oncology NASDAQ:ELEV

$0.38 0.00 (-0.92%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$0.38 +0.00 (+0.11%)
As of 07/10/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

Miromatrix Medical stock logo

Miromatrix Medical NASDAQ:MIRO

Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. The company's proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. It has collaborations with Baxter, CareDx, The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.